Physician profile
Mary E Sheffield
NPI 1811100050
$3,122.50
in general payments reported to CMS, 2019-2025
46 companies · $850 in 2025
The $850 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $74.95 · 2021: $180 · 2022: $702 · 2023: $519 · 2024: $678 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000 · Education: $47.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.80 |
| Education | $47.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $358.62 | 2019-2025 | |
| Janssen Biotech, INC. | $240.42 | 2019-2025 | Darzalex, Carvykti, Erleada |
| E.R. Squibb & Sons, L.L.C. | $204.65 | 2022-2025 | Opdivo, Opdualag, Augtyro |
| Amgen INC. | $178.14 | 2019-2023 | Prolia, Evenity, Kyprolis |
| Gilead Sciences, INC. | $155.21 | 2021-2025 | Trodelvy |
| Eisai INC. | $128.42 | 2022-2025 | |
| Pfizer INC. | $127.64 | 2020-2025 | |
| Celgene Corporation | $109.46 | 2019-2025 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $108.73 | 2023-2025 | Polivy, Venclexta, Itovebi |
| Regeneron Healthcare Solutions, INC. | $102.08 | 2019-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $88.12 | 2022-2025 | |
| Lilly USA, LLC | $83.66 | 2022-2024 | Verzenio, Retevmo, Jaypirca |
| Pharmacosmos Therapeutics INC. | $77.46 | 2021-2025 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $72.42 | 2022-2025 | Imfinzi, Calquence |
| Glaxosmithkline, LLC. | $68.26 | 2021-2025 | Ojjaara |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $66.79 | 2022 | |
| Incyte Corporation | $63.38 | 2024-2025 | Jakafi, Monjuvi |
| Aveo Pharmaceuticals, INC. | $51.49 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.27 | 2024-2025 | Ninlaro, Fruzaqla |
| Stemline Therapeutics INC. | $46.54 | 2023-2024 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $45.22 | 2024-2025 | Onivyde, Somatuline Depot |
| Genmab U.S., INC. | $44.33 | 2023-2024 | Epkinly |
| Karyopharm Therapeutics INC. | $41.71 | 2022-2023 | Xpovio |
| Array Biopharma INC | $41.42 | 2024-2025 | Lorbrena, Mektovi, Xalkori |
| Genzyme Corporation | $40.20 | 2022-2025 | |
| Astellas Pharma US INC | $39.90 | 2024-2025 | Vyloy, Xtandi |
| Sumitomo Pharma America, INC. | $39.80 | 2023-2025 | Orgovyx |
| Daiichi Sankyo INC. | $39.18 | 2024-2025 | Datroway, Enhertu |
| Beigene USA, INC. | $36.78 | 2022-2023 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $36.12 | 2024-2025 | Qinlock, Romvimza |
| Jazz Pharmaceuticals INC. | $35.06 | 2024 | |
| Abbvie INC. | $26.05 | 2024 | |
| Exelixis INC. | $25.61 | 2025 | Cabometyx |
| Kyowa Kirin, INC. | $24.45 | 2025 | |
| Merck Sharp & Dohme LLC | $24.36 | 2025 | Keytruda, Welireg |
| Beone Medicines USA, INC. | $23.54 | 2025 | Brukinsa |
| Puma Biotechnology, INC. | $21.13 | 2025 | |
| Adaptive Biotechnologies Corporation | $20.76 | 2025 | Clonoseq |
| Coherus Oncology, INC. | $19.90 | 2025 | Udenyca |
| Janssen Pharmaceuticals, INC | $19.08 | 2022 | |
| Progenics Pharmaceuticals, INC. | $18.78 | 2022 | |
| Adc Therapeutics America, INC. | $18.73 | 2022 | |
| Eusa Pharma (US) LLC | $18.22 | 2019 | |
| Rigel Pharmaceuticals, INC. | $15.95 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Lexicon Pharmaceuticals, INC. | $14.68 | 2020 | |
| Global Blood Therapeutics, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Sheffield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.